SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Bristol-Myers Squibb Company PFD CONV 2 BMYMP OTC

Other OTC • Healthcare • Drug Manufacturers - General • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $400.00. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 0 out of 7 criteria passed.

Financials: revenue is $48.2B, +1.5%/yr average growth. Net income is $7.1B, growing at -1.9%/yr. Net profit margin is 14.6% (healthy). Gross margin is 67.6% (-10.4 pp trend).

Balance sheet: total debt is $47.1B against $18.5B equity (Debt-to-Equity (D/E) ratio 2.55, leveraged). Current ratio is 1.26 (adequate). Debt-to-assets is 52.4%. Total assets: $90.0B.

Analyst outlook: 4 / 8 analysts rate BMYMP as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 15/100 (Fail), Growth 30/100 (Fail), Past 75/100 (Partial), Health 50/100 (Partial), Moat 51/100 (Partial), Future 40/100 (Partial), Income 55/100 (Partial).

BMYMP SharesGrow Score Overview

45/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 15/100

Valuation — P/E, PEG, Forward PEG

GROWTH 30/100

Financials — average growth

PAST 75/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 51/100

Gross margin is + market cap

FUTURE 40/100

Analyst outlook — as buy

INCOME 55/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BMYMP

BMYMP trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

BMYMP: +1.5%/yr revenue is, -1.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

BMYMP: 3 / 4 years profitable. mixed. Score = 3 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet BMYMP: Debt-to-Equity (D/E) ratio 2.55 (leveraged), Current ratio is 1.26 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

BMYMP: Gross margin is 67.6% (-10.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 51/100. ≥ 70 = Pass.

View details →

Analyst outlook: 4 / 8 analysts rate BMYMP as buy (50%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

BMYMP: Net profit margin is 14.6%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range400-1050

Volume13

Avg Volume (30D)2

Beta (1Y)0.27

Dividend Yield$2.0000

Share Statistics

EPS (TTM)3.46

Shares Outstanding$2.04B

IPO Date2003-12-08

Employees34,100

CEOChristopher S. Boerner

Financial Highlights & Ratios

Revenue (TTM)$48.19B

Gross Profit$32.6B

EBITDA$14.55B

Net Income$7.05B

Operating Income$12.7B

Total Cash$10.67B

Total Debt$47.14B

Net Debt$36.93B

Total Assets$90.04B

Price / Earnings (P/E)115.6

Analyst Forecast

Rating ConsensusBuy

Analysts Covering8

Buy 50% Hold 38% Sell 13%

Company Info

CountryUS

ExchangeOther OTC

CurrencyUSD

ISINUS1101222073

Price Chart

BMYMP

Bristol-Myers Squibb Company PFD CONV 2 ↗ · Other OTC

Healthcare • Drug Manufacturers - General

400.00 52WK RANGE 1,050.00

People Also View

Roche Holding AG

Roche Holding AG

AstraZeneca PLC

AstraZeneca PLC

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message